scholarly journals Prevention with 240 mg Galcanezumab of Episodic Cluster Headache

2021 ◽  
Vol 39 (3) ◽  
pp. 228-229
Author(s):  
Heejung Mo ◽  
Min Jun Song ◽  
Soo-Jin Cho
Keyword(s):  
Cluster Headache ◽  
Episodic Cluster Headache

Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure

2021 ◽  
Vol 4 ◽  
pp. 251581632110156
Author(s):  
Brian Plato ◽  
J Scott Andrews ◽  
Mallikarjuna Rettiganti ◽  
Antje Tockhorn-Heidenreich ◽  
Jennifer Bardos ◽  
...  
Keyword(s):  
Cluster Headache ◽  
Treatment Failure ◽  
Preventive Treatment ◽  
Mean Difference ◽  
Least Square ◽  
Double Blind Study ◽  
Double Blind ◽  
Cluster Headache Attack ◽  
Episodic Cluster Headache ◽  
History Of

Objective: The efficacy of galcanezumab was evaluated in patients with episodic cluster headache and history of preventive treatment failure. Methods: In the randomized, 8-week, double-blind study (CGAL), patients with episodic cluster headache received once-monthly subcutaneous injections of galcanezumab 300 mg or placebo. Patients who completed CGAL and enrolled in an open-label study were queried for preventive treatment history. In a subset of patients with a known history of failure of verapamil or any other prior preventive treatment, a post hoc analysis of least square mean change from baseline in weekly cluster headache attack frequency across Weeks 1 to 3 was assessed. Results: Fifteen patients provided data for known history of prior preventive treatment failure (6 placebo, 9 galcanezumab), of whom 11 failed verapamil. The mean reduction in the weekly frequency of cluster headache attacks was greater with galcanezumab compared to placebo among patients with prior preventive treatment failure (8.2 versus 2.4); mean difference 5.8 (95% confidence interval [CI] 2.0, 13.6) and among patients with verapamil failure (10.1 versus 1.6); mean difference 8.5 (95% CI 0.4, 16.7). Conclusion: In this exploratory analysis of patients with a known history of prior preventive treatment failures, treatment with galcanezumab resulted in greater mean reductions in weekly cluster headache attacks compared with placebo. ClinicalTrials.gov: NCT02397473 (I5Q-MC-CGAL) NCT02797951 (I5Q-MC-CGAR)

scholarly journals Efficacy of transdermal rotigotine in chronic cluster headache: A case series

2018 ◽  
Vol 1 ◽  
pp. 251581631880969
Author(s):  
Cherubino Di Lorenzo ◽  
Lanfranco Pellesi ◽  
Gianluca Coppola ◽  
Vincenzo Parisi ◽  
Maurizio Evangelista ◽  
...  
Keyword(s):  
Cluster Headache ◽  
Case Series ◽  
Chronic Cluster Headache ◽  
Drug Resistant ◽  
Transdermal Patch ◽  
Full Resolution ◽  
Episodic Cluster Headache ◽  
Monoaminergic System ◽  
Rotigotine Transdermal Patch ◽  
Effective Treatments

Cluster headache (CH) is one of the most severe forms of headache, but the number of effective treatments is still limited. Recently, we reported the case of a drug-resistant CH patient responsive to the rotigotine transdermal patch, which is used in the treatment of Parkinson’s disease. This report formed the basis for a case series where other drug-resistant CH patients were treated with rotigotine. Here are the results of this study. Twenty-two CH patients underwent the treatment. Eight were episodic cluster headache (ECH) patients and 14 were chronic cluster headache (CCH) patients. Of the eight ECH patients, four reported that their CH had been stopped by the treatment. Of the 14 CCH patients, 11 were considered responders to the treatment (5 experienced a full resolution of headache, and 6 had a headache reduction of at least 50% in terms of mean monthly number of attacks). Our case series confirms the previous observation that rotigotine could be helpful in the treatment of CH. It may even influence the monoaminergic system that has a key role in the pathogenesis of CH.

scholarly journals Use of High Sumatriptan Dosages During Episodic Cluster Headache: Three Clinical Cases

1996 ◽  
Vol 36 (6) ◽  
pp. 389-391 ◽  
Author(s):  
V. Centonze ◽  
B.M. Polito ◽  
E. Attolini ◽  
M.A. Cassiano ◽  
C. Sabba ◽  
...  
Keyword(s):  
Cluster Headache ◽  
Episodic Cluster Headache ◽  
Clinical Cases

Lack of β-Endorphin and β-Lipotropin Circadian Rhythmicity in Episodic Cluster Headache: A Model for Chronopathology

1985 ◽  
pp. 269-275 ◽  
Author(s):  
G. Nappi ◽  
F. Facchinetti ◽  
G. Bono ◽  
F. Petraglia ◽  
G. Micieli ◽  
...  
Keyword(s):  
Cluster Headache ◽  
Circadian Rhythmicity ◽  
Episodic Cluster Headache

scholarly journals Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache

2020 ◽  
Vol 60 (10) ◽  
pp. 2254-2264
Author(s):  
David Kudrow ◽  
J. Scott Andrews ◽  
Mallikarjuna Rettiganti ◽  
Tina Oakes ◽  
Jennifer Bardos ◽  
...  
Keyword(s):  
Cluster Headache ◽  
Treatment Outcomes ◽  
Randomized Study ◽  
Phase 3 ◽  
Episodic Cluster Headache ◽  
Post Hoc

Hemicrania Continua with Contralateral Episodic Cluster Headache: A Case Report

Cephalalgia ◽  
2003 ◽  
Vol 23 (9) ◽  
pp. 929-930 ◽  
Author(s):  
C Lisotto ◽  
F Mainardi ◽  
F Maggioni ◽  
G Zanchin
Keyword(s):  
Case Report ◽  
Cluster Headache ◽  
Hemicrania Continua ◽  
Paroxysmal Hemicrania ◽  
Simultaneous Occurrence ◽  
Headache Disorders ◽  
Sunct Syndrome ◽  
First Case ◽  
Episodic Cluster Headache ◽  
Male Patients

The trigeminal autonomic cephalgias (TACs) are characterized by short-lasting unilateral headaches with autonomic features (1). They include four headache disorders, cluster headache (CH), paroxysmal hemicrania (PH), SUNCT syndrome and hemicrania continua (HC). The coexistence of different ipsilateral TACs in the same patient has been previously reported in six published cases (2-6). In five of these patients an association of CH and PH was noted (2-5). The two varieties of attacks occurred separately in three patients, while their simultaneous occurrence was observed in two cases. In another patient the successive occurrence of trigeminal neuralgia, SUNCT syndrome, PH and CH in one active headache period was noted (6). All the reported cases concerned male patients. We describe what we believe to be the first case of coexistence of two different contralateral TACs.

Sign in / Sign up

Export Citation Format

Share Document